Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 15/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30347211 | 1.00 | TDO2 (0.40) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL25199262 | 0.97 | TDO2 (0.40) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL30346463 | 0.97 | TDO2 (0.40) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL30347948 | 0.96 | TDO2 (0.41) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL25156953 | 0.96 | TDO2 (0.41) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL25157800 | 0.91 | TDO2 (0.38) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL30347290 | 0.91 | TDO2 (0.38) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL25195220 | 0.88 | TDO2 (0.38) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL30347881 | 0.88 | TDO2 (0.38) | TDO2CLK2CLK3DYRK1ABRD4 | |
| SCHEMBL25157455 | 0.88 | TDO2 (0.41) | TDO2CLK2CLK3DYRK1ABRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2025-04-24 | — | — | US | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | claimed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167133-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TDO2 539/4885CLK2 466/4885CLK3 1147/4885 |
| US-20250129104-A1 | 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | TDO2 539/4885CLK2 466/4885CLK3 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.